Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ned Tijdschr Geneeskd ; 152(12): 657-62, 2008 Mar 22.
Artigo em Holandês | MEDLINE | ID: mdl-18438058

RESUMO

Eosinophilic fasciitis (EF) is a disease with unknown aetiology, although an immunologic pathogenesis is suspected. The characteristic features of this inflammatory disease include scleroderma-like skin indurations, predominantly on the extremities, and peripheral blood eosinophilia. Internal organs are generally not affected. Initiation of systemic glucocorticoid therapy at an early stage results in a good response and remission of symptoms. This is illustrated in 3 cases of EF to demonstrate the importance of early detection in this disease.


Assuntos
Eosinofilia/diagnóstico , Fasciite/diagnóstico , Glucocorticoides/uso terapêutico , Contratura/diagnóstico , Contratura/etiologia , Contratura/patologia , Eosinofilia/tratamento farmacológico , Eosinofilia/patologia , Fasciite/tratamento farmacológico , Fasciite/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pele/patologia , Fatores de Tempo , Resultado do Tratamento
2.
Clin Exp Immunol ; 152(2): 227-32, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18336594

RESUMO

Secretory immunoglobulin A (SIgA), although generated at mucosal surfaces, is also found in low concentrations in the circulation. Recently, SIgA was demonstrated in mesangial deposits of patients with immunoglobulin A nephropathy (IgAN), suggesting a role in the pathogenesis. This finding is in line with the belief that high molecular weight (HMW) immunoglobulin A (IgA) is deposited in the kidney. However, there is little information on the size distribution of antigen-specific IgA in circulation upon mucosal challenge. In this study we measured antigen-specific IgA, including SIgA, in serum following challenge of IgAN patients and controls via intranasal vaccination with a neoantigen, cholera toxin subunit B (CTB). We size-fractionated serum and nasal washes to study the size distribution of total IgA, SIgA and CTB-specific IgA. Finally, we compared the size distribution of antigen-specific IgA after mucosal immunization with the distribution upon systemic immunization. A significant induction of antigen-specific SIgA was detectable in serum of both patients with IgAN and controls after mucosal immunization with CTB. Independent of the route of immunization, in both groups the antigen-specific IgA response was predominantly in the polymeric IgA fractions. This is in contrast to total IgA levels in serum that are predominantly monomeric. We conclude that mucosal challenge results in antigen-specific SIgA in the circulation, and that the antigen-specific IgA response in both IgAN patients and in controls is of predominantly HMW in nature. No differences between IgAN patients and controls were detected, suggesting that the size distribution of antigen-specific IgA in the circulation is not disturbed specifically in IgAN patients.


Assuntos
Glomerulonefrite por IGA/imunologia , Imunoglobulina A Secretora/biossíntese , Imunoglobulina A/biossíntese , Administração Intranasal , Adulto , Toxina da Cólera/administração & dosagem , Toxina da Cólera/imunologia , Epitopos , Feminino , Humanos , Imunidade nas Mucosas , Imunização/métodos , Imunoglobulina A/sangue , Imunoglobulina A Secretora/sangue , Masculino , Pessoa de Meia-Idade , Cavidade Nasal/imunologia
3.
Nephrol Dial Transplant ; 21 Suppl 2: ii34-7, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16825258

RESUMO

The well-being and survival of dialysis patients not only depend on the removal of waste products and excess fluid, but also on the prevention of cardiovascular complications by maintaining normovolaemia and adequate blood pressure and avoidance of ectopic calcification. Also, the maintenance of nutritional status and adequate removal of middle molecules are amongst the most important issues in long-term renal replacement therapy. In this review, attention is given to optimal peritoneal small solute clearance and Kt/V and to the evidence concerning the role of residual renal function. In addition, factors that can influence this residual function are also discussed.


Assuntos
Nefropatias/terapia , Rim/fisiopatologia , Diálise Peritoneal , Creatinina/metabolismo , Humanos , Nefropatias/fisiopatologia , Testes de Função Renal , Taxa de Depuração Metabólica , Estado Nutricional , Garantia da Qualidade dos Cuidados de Saúde
4.
Kidney Int ; 70(4): 732-42, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16820790

RESUMO

Until recently, intravenous cyclophosphamide pulses with oral corticosteroids were regarded standard therapy for proliferative lupus nephritis (LN). Azathioprine, a less toxic alternative, was never proven to be inferior. In the first Dutch lupus nephritis study (enrollment between 1995 and 2001), we randomized 87 proliferative LN patients to either cyclophosphamide pulses (750 mg/m(2), 13 pulses in 2 years) combined with oral prednisone (CY) or to azathioprine (2 mg/kg/day in 2 years) combined with intravenous pulses of methylprednisolone (3 x 3 pulses of 1000 mg) and oral prednisone (AZA). After a median follow-up of 5.7 years (interquartile range 4.1-7.2 years), doubling of serum creatinine was more frequent in the AZA group, although not statistically significant (relative risk (RR): 4.1, with 95% confidence interval (95% CI): 0.8-20.4). Relapses occurred more often in the AZA group (RR: 8.8, 95% CI: 1.5-31.8). Creatinine and proteinuria at last visit did not differ between the two treatment arms. Moreover, 88.4% of the patients in the AZA arm were still free of cyclophosphamide treatment. During the first 2 years, the frequency of remission was not different, but infections, especially herpes zoster virus infections (HZV) were more frequent in the AZA group. Parameters for ovarian function did not differ between the two groups. In conclusion, in this open-label randomized controlled trial, cyclophosphamide was superior to azathioprine with regard to renal relapses and HZV. At last follow-up, there were no differences in serum creatinine or proteinuria between the two groups. However, since our study lacked sufficient power, longer follow-up is needed to reveal putative differences.


Assuntos
Anti-Inflamatórios/uso terapêutico , Azatioprina/uso terapêutico , Ciclofosfamida/uso terapêutico , Imunossupressores/uso terapêutico , Nefrite Lúpica/tratamento farmacológico , Metilprednisolona/uso terapêutico , Administração Oral , Adolescente , Adulto , Anti-Inflamatórios/administração & dosagem , Azatioprina/administração & dosagem , Creatinina/sangue , Ciclofosfamida/administração & dosagem , Quimioterapia Combinada , Feminino , Humanos , Imunossupressores/administração & dosagem , Injeções Intravenosas , Nefrite Lúpica/sangue , Nefrite Lúpica/patologia , Masculino , Metilprednisolona/administração & dosagem , Pessoa de Meia-Idade , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Prednisolona/administração & dosagem , Prednisolona/uso terapêutico , Indução de Remissão , Resultado do Tratamento
5.
Qual Life Res ; 12(6): 635-44, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-14516173

RESUMO

Reliable and sensitive measures are needed to evaluate the quality of life (QoL) in patients with systemic lupus erythematosus (SLE). No lupus specific questionnaires are available. This study describes the development and validation of a disease-specific questionnaire for lupus patients, which assesses the presence and burden of 38 disease- and treatment-related symptoms: the SLE Symptom Checklist (SSC). Reliability and reproducibility were tested in respectively 87 and 28 stable SLE patients. The internal consistency (Cronbach's alpha coefficients 0.89) and test-retest reliability (Pearson product-moment correlation coefficient between 0.67 and 0.87) were satisfactory. Concurrent validity was supported by significant, but moderate correlations with other measures of subjective well-being and functional status. Responsiveness was measured in 17 patients with lupus nephritis treated with cyclophosphamide, at start of therapy and 1 year thereafter. A significant change in number of symptoms and total distress level was found. It is concluded that the SSC has satisfactory psychometric properties and appears suitable for both clinical and research purposes.


Assuntos
Lúpus Eritematoso Sistêmico/fisiopatologia , Qualidade de Vida , Perfil de Impacto da Doença , Feminino , Nível de Saúde , Humanos , Lúpus Eritematoso Sistêmico/psicologia , Masculino , Inquéritos e Questionários
6.
J Cardiovasc Surg (Torino) ; 43(4): 483-8, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12124559

RESUMO

BACKGROUND: Renal failure after lower torso ischemia is a serious problem, partly caused by hypotension and indirect reperfusion injury. This injury is partly due to the formation of oxygen free radicals by activated neutrophils. This injury results in albuminuria and renal function impairment. There are indications that free radical damage in indirect reperfusion injury can be diminished by administering extra antioxidants before and during reperfusion. METHODS: In this prospective randomised study we have looked at the influence of a multi-antioxidant supplementation on renal function in patients undergoing an elective open infrarenal abdominal aneurysm repair. The patients received either standard treatment (n=22) or standard treatment with additional antioxidants perioperatively (Allopurinol, vitamin E and C, N-acetylcysteine and mannitol). For renal function we have looked at the albumin/creatinine ratio in urine and 24 hr creatinine clearance. RESULTS: Despite significantly increased serum total antioxidant capacity, the group receiving extra antioxidants showed no decrease in the albumin/creatinine ratio in urine. There was however a significantly higher creatinine clearance in this group at day 2. CONCLUSIONS: The results indicate that the diminished renal function after infrarenal aneurysm repair may be influenced by antioxidant therapy.


Assuntos
Antioxidantes/uso terapêutico , Aneurisma da Aorta Abdominal/cirurgia , Insuficiência Renal/tratamento farmacológico , Traumatismo por Reperfusão/tratamento farmacológico , Acetilcisteína/uso terapêutico , Idoso , Albuminúria/prevenção & controle , Alopurinol/uso terapêutico , Ácido Ascórbico/uso terapêutico , Feminino , Humanos , Testes de Função Renal , Masculino , Manitol/uso terapêutico , Estudos Prospectivos , Insuficiência Renal/fisiopatologia , Traumatismo por Reperfusão/fisiopatologia , Vitamina E/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...